Inovio Pharmaceuticals is a Pennsylvania-based biotech company that's on the cutting edge of the search for a coronavirus vaccine.
Continue Reading Below
The company received a $71 million grant from the Department of Defense on June 23 to scale up its Cellectra intradermal DNA vaccine delivery device.
"The current DoD contract further supports INOVIO's large-scale production of devices and arrays to deliver potentially hundreds of millions of doses of INO-4800 next year to combat the global COVID-19 pandemic," Dr. J. Joseph Kim, Inovio's president and CEO, said in a statement.
Inovio already received $10 million from billionaire Bill Gates' Coalition for Epidemic Preparedness Innovations to accelerate testing of the device.
Earlier in the year, Inovio said it created a coronavirus vaccine hours after getting access to the genetic sequence in mid-January.
"We were able to rapidly construct our vaccine in a matter of about three hours once we had the DNA sequence from the virus available because of the power of our DNA medicine platform," Dr. J. Joseph Kim, Inovio's president and CEO, told FOX Business in February.
With help from CEPI, Inovio is testing the vaccine in South Korea.
The company was founded in 1979 and focuses on finding DNA medicines for cancer, Ebola, AIDS and other diseases, according to Yahoo Finance.